{"doc_id": "32641343", "type of study": "Therapy", "title": "", "abstract": "Intravenous high-dose vitamin C for the treatment of severe COVID-19: study protocol for a multicentre randomised controlled trial.\nThe rapid worldwide spread of COVID-19 has caused a global health crisis.\nTo date, symptomatic supportive care has been the most common treatment.\nIt has been reported that the mechanism of COVID-19 is related to cytokine storms and subsequent immunogenic damage, especially damage to the endothelium and alveolar membrane.\nVitamin C (VC), also known as L-ascorbic acid, has been shown to have antimicrobial and immunomodulatory properties.\nA high dose of intravenous VC (HIVC) was proven to block several key components of cytokine storms, and HIVC showed safety and varying degrees of efficacy in clinical trials conducted on patients with bacterial-induced sepsis and acute respiratory distress syndrome (ARDS).\nTherefore, we hypothesise that HIVC could be added to the treatment of ARDS and multiorgan dysfunction related to COVID-19.\nMETHODS AND ANALYSIS : The investigators designed a multicentre prospective randomised placebo-controlled trial that is planned to recruit 308 adults diagnosed with COVID-19 and transferred into the intensive care unit.\nParticipants will randomly receive HIVC diluted in sterile water or placebo for 7 days once enrolled.\nPatients with a history of VC allergy, end-stage pulmonary disease, advanced malignancy or glucose-6-phosphate dehydrogenase deficiency will be excluded.\nThe primary outcome is ventilation-free days within 28 observational days.\nThis is one of the first clinical trials applying HIVC to treat COVID-19, and it will provide credible efficacy and safety data.\nWe predict that HIVC could suppress cytokine storms caused by COVID-19, help improve pulmonary function and reduce the risk of ARDS of COVID-19.\nETHICS AND DISSEMINATION : The study protocol was approved by the Ethics Committee of Zhongnan Hospital of Wuhan University (identifiers: Clinical Ethical Approval No. 2020001).\nFindings of the trial will be disseminated through peer-reviewed journals and scientific conferences.\nTRIAL REGISTRATION NUMBER : NCT04264533.\n\u00a9 Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC.\nNo commercial re-use. See rights and permissions.\nPublished by BMJ.\n", "Evidence Map": {"Enrollment": [{"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 53, "end": 68}, {"term": "bacterial-induced sepsis", "negation": "affirmed", "UMLS": {}, "start": 204, "end": 228}, {"term": "acute respiratory", "negation": "affirmed", "UMLS": {}, "start": 233, "end": 250}, {"term": "ARDS", "negation": "affirmed", "UMLS": {}, "start": 72, "end": 76}, {"term": "multiorgan dysfunction related to", "negation": "affirmed", "UMLS": {}, "start": 81, "end": 114}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 165, "end": 173}, {"term": "VC allergy", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 37}, {"term": "end-stage pulmonary disease", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 67}, {"term": "advanced malignancy", "negation": "affirmed", "UMLS": {}, "start": 70, "end": 89}, {"term": "glucose-6-phosphate dehydrogenase deficiency", "negation": "affirmed", "UMLS": {}, "start": 93, "end": 137}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Intravenous high-dose vitamin C for the treatment of severe COVID-19 : study protocol for a multicentre randomised controlled trial .", "Evidence Elements": {"Participant": [{"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 53, "end": 68}], "Intervention": [{"term": "Intravenous high-dose vitamin C", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 31, "has_chemical": [{"text": "vitamin", "maps_to": "C0042890:vitamin", "start": 22, "end": 29, "has_route": ["intravenous"], "has_dosage": ["high dose"]}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "INTRODUCTION", "Text": "The rapid worldwide spread of COVID-19 has caused a global health crisis .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "INTRODUCTION", "Text": "To date , symptomatic supportive care has been the most common treatment .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "INTRODUCTION", "Text": "It has been reported that the mechanism of COVID-19 is related to cytokine storms and subsequent immunogenic damage , especially damage to the endothelium and alveolar membrane .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "INTRODUCTION", "Text": "Vitamin C ( VC ) , also known as L-ascorbic acid , has been shown to have antimicrobial and immunomodulatory properties .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "INTRODUCTION", "Text": "A high dose of intravenous VC ( HIVC ) was proven to block several key components of cytokine storms , and HIVC showed safety and varying degrees of efficacy in clinical trials conducted on patients with bacterial-induced sepsis and acute respiratory distress syndrome ( ARDS ) .", "Evidence Elements": {"Participant": [{"term": "bacterial-induced sepsis", "negation": "affirmed", "UMLS": {}, "start": 204, "end": 228}, {"term": "acute respiratory", "negation": "affirmed", "UMLS": {}, "start": 233, "end": 250}], "Intervention": [{"term": "high dose of intravenous VC ( HIVC )", "negation": "affirmed", "UMLS": {}, "start": 2, "end": 38, "has_chemical": [{"text": "vitamin", "maps_to": "C0042890:vitamin", "start": 25, "end": 32, "has_route": ["intravenous"], "has_dosage": ["high dose"]}], "has_relation": "N/A"}, {"term": "HIVC", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 36, "has_relation": "N/A"}], "Outcome": [{"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 119, "end": 125}, {"term": "efficacy", "negation": "affirmed", "UMLS": {}, "start": 149, "end": 157}], "Observation": [{"term": "varying", "negation": "affirmed", "UMLS": {}, "start": 130, "end": 137}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "HIVC", "has_relation": "N/A"}, "Observation": "varying", "Outcome": "efficacy", "Count": ""}]}, {"Section": "INTRODUCTION", "Text": "Therefore , we hypothesise that HIVC could be added to the treatment of ARDS and multiorgan dysfunction related to COVID-19 .", "Evidence Elements": {"Participant": [{"term": "ARDS", "negation": "affirmed", "UMLS": {}, "start": 72, "end": 76}, {"term": "multiorgan dysfunction related to", "negation": "affirmed", "UMLS": {}, "start": 81, "end": 114}], "Intervention": [{"term": "HIVC", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 36, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "METHODS AND ANALYSIS : The investigators designed a multicentre prospective randomised placebo-controlled trial that is planned to recruit 308 adults diagnosed with COVID-19 and transferred into the intensive care unit .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 165, "end": 173}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Participants will randomly receive HIVC diluted in sterile water or placebo for 7 days once enrolled .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "HIVC", "negation": "affirmed", "UMLS": {}, "start": 35, "end": 39, "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 68, "end": 75, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Patients with a history of VC allergy , end-stage pulmonary disease , advanced malignancy or glucose-6-phosphate dehydrogenase deficiency will be excluded .", "Evidence Elements": {"Participant": [{"term": "VC allergy", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 37}, {"term": "end-stage pulmonary disease", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 67}, {"term": "advanced malignancy", "negation": "affirmed", "UMLS": {}, "start": 70, "end": 89}, {"term": "glucose-6-phosphate dehydrogenase deficiency", "negation": "affirmed", "UMLS": {}, "start": 93, "end": 137}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The primary outcome is ventilation-free days within 28 observational days .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "ventilation-free days", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 44}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "This is one of the first clinical trials applying HIVC to treat COVID-19 , and it will provide credible efficacy and safety data .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "We predict that HIVC could suppress cytokine storms caused by COVID-19 , help improve pulmonary function and reduce the risk of ARDS of COVID-19 .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "HIVC", "negation": "affirmed", "UMLS": {}, "start": 16, "end": 20, "has_relation": "N/A"}], "Outcome": [{"term": "cytokine storms", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 51}, {"term": "pulmonary function", "negation": "affirmed", "UMLS": {}, "start": 86, "end": 104}, {"term": "risk of ARDS", "negation": "affirmed", "UMLS": {}, "start": 120, "end": 132}], "Observation": [{"term": "suppress", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 35}, {"term": "improve", "negation": "affirmed", "UMLS": {}, "start": 78, "end": 85}, {"term": "reduce", "negation": "affirmed", "UMLS": {}, "start": 109, "end": 115}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "HIVC", "has_relation": "N/A"}, "Observation": "reduce", "Outcome": "risk of ARDS", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "ETHICS AND DISSEMINATION : The study protocol was approved by the Ethics Committee of Zhongnan Hospital of Wuhan University ( identifiers : Clinical Ethical Approval No . 2020001 ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Findings of the trial will be disseminated through peer-reviewed journals and scientific conferences .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "TRIAL REGISTRATION NUMBER : NCT04264533 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "\u00a9 Author (s ) ( or their employer (s ) ) 2020 . Re-use permitted under CC BY-NC .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "No commercial re-use . See rights and permissions .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Published by BMJ .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}